Tag: Cytokine release syndrome

The term "bite therapy" can refer to two entirely different medical treatments: dental solutions for jaw alignment and teeth grinding, or a specific type of cancer immunotherapy called Bispecific T-cell Engager (BiTE) therapy. Each carries a distinct set of potential side effects, making it crucial to understand which treatment is being discussed.

Tocilizumab is a biologic medication that blocks the inflammatory protein interleukin-6 (IL-6), and its approval for treating various conditions, such as rheumatoid arthritis, has transformed patient care. So, **what is tocilizumab used to treat?** This powerful medication has several key applications, leveraging its ability to modulate the immune response and reduce severe inflammation.

Tebentafusp was the first-in-class T-cell receptor therapeutic to be approved by the FDA, representing a significant breakthrough in cancer treatment. This innovative immunotherapy, also known by its brand name Kimmtrak, is a targeted therapy for adults with unresectable or metastatic uveal melanoma.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) as the first T-cell receptor (TCR) therapeutic for a solid tumor, representing a significant advancement in oncology. So, **what is kimmtrak?** This bispecific fusion protein is indicated for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.